Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Thyroid Cancer Patients With No Evidence of Disease: The Need for Repeat Neck Ultrasound.

Grani G, Ramundo V, Falcone R, Lamartina L, Montesano T, Biffoni M, Giacomelli L, Sponziello M, Verrienti A, Schlumberger M, Filetti S, Durante C.

J Clin Endocrinol Metab. 2019 Nov 1;104(11):4981-4989. doi: 10.1210/jc.2019-00962.

PMID:
31206157
2.

Expression of Leptin Receptor and Effects of Leptin on Papillary Thyroid Carcinoma Cells.

Celano M, Maggisano V, Lepore SM, Sponziello M, Pecce V, Verrienti A, Durante C, Maranghi M, Lucia P, Bulotta S, Damante G, Russo D.

Int J Endocrinol. 2019 Feb 14;2019:5031696. doi: 10.1155/2019/5031696. eCollection 2019.

3.

BRAFV600E-mutant cancers display a variety of networks by SWIM analysis: prediction of vemurafenib clinical response.

Falcone R, Conte F, Fiscon G, Pecce V, Sponziello M, Durante C, Farina L, Filetti S, Paci P, Verrienti A.

Endocrine. 2019 May;64(2):406-413. doi: 10.1007/s12020-019-01890-4. Epub 2019 Mar 8.

PMID:
30850937
4.

Human telomerase reverse transcriptase in papillary thyroid cancer: gene expression, effects of silencing and regulation by BET inhibitors in thyroid cancer cells.

Maggisano V, Celano M, Lepore SM, Sponziello M, Rosignolo F, Pecce V, Verrienti A, Baldan F, Mio C, Allegri L, Maranghi M, Falcone R, Damante G, Russo D, Bulotta S.

Endocrine. 2019 Mar;63(3):545-553. doi: 10.1007/s12020-018-01836-2. Epub 2019 Jan 19.

PMID:
30661164
5.

A synonymous RET substitution enhances the oncogenic effect of an in-cis missense mutation by increasing constitutive splicing efficiency.

Pecce V, Sponziello M, Damante G, Rosignolo F, Durante C, Lamartina L, Grani G, Russo D, di Gioia CR, Filetti S, Verrienti A.

PLoS Genet. 2018 Oct 15;14(10):e1007678. doi: 10.1371/journal.pgen.1007678. eCollection 2018 Oct.

6.

A novel nonsense EIF1AX mutation identified in a thyroid nodule histologically diagnosed as oncocytic carcinoma.

Sponziello M, Silvestri G, Verrienti A, Perna A, Rosignolo F, Brunelli C, Pecce V, Rossi ED, Lombardi CP, Durante C, Filetti S, Fadda G.

Endocrine. 2018 Nov;62(2):492-495. doi: 10.1007/s12020-018-1611-7. Epub 2018 Apr 26. No abstract available.

PMID:
29700698
7.

Evaluation of Polygenic Determinants of Non-Alcoholic Fatty Liver Disease (NAFLD) By a Candidate Genes Resequencing Strategy.

Di Costanzo A, Belardinilli F, Bailetti D, Sponziello M, D'Erasmo L, Polimeni L, Baratta F, Pastori D, Ceci F, Montali A, Girelli G, De Masi B, Angeloni A, Giannini G, Del Ben M, Angelico F, Arca M.

Sci Rep. 2018 Feb 27;8(1):3702. doi: 10.1038/s41598-018-21939-0.

8.

Identification of Thyroid-Associated Serum microRNA Profiles and Their Potential Use in Thyroid Cancer Follow-Up.

Rosignolo F, Sponziello M, Giacomelli L, Russo D, Pecce V, Biffoni M, Bellantone R, Lombardi CP, Lamartina L, Grani G, Durante C, Filetti S, Verrienti A.

J Endocr Soc. 2017 Jan 12;1(1):3-13. doi: 10.1210/js.2016-1032. eCollection 2017 Jan 1.

9.

BET bromodomain inhibitor JQ1 modulates microRNA expression in thyroid cancer cells.

Mio C, Conzatti K, Baldan F, Allegri L, Sponziello M, Rosignolo F, Russo D, Filetti S, Damante G.

Oncol Rep. 2018 Feb;39(2):582-588. doi: 10.3892/or.2017.6152. Epub 2017 Dec 12.

PMID:
29251329
10.

Whole exome sequencing identifies a germline MET mutation in two siblings with hereditary wild-type RET medullary thyroid cancer.

Sponziello M, Benvenuti S, Gentile A, Pecce V, Rosignolo F, Virzì AR, Milan M, Comoglio PM, Londin E, Fortina P, Barnabei A, Appetecchia M, Marandino F, Russo D, Filetti S, Durante C, Verrienti A.

Hum Mutat. 2018 Mar;39(3):371-377. doi: 10.1002/humu.23378. Epub 2017 Dec 20.

PMID:
29219214
11.

Targeting post-translational histone modifications for the treatment of non-medullary thyroid cancer.

Celano M, Mio C, Sponziello M, Verrienti A, Bulotta S, Durante C, Damante G, Russo D.

Mol Cell Endocrinol. 2018 Jul 5;469:38-47. doi: 10.1016/j.mce.2017.05.036. Epub 2017 Jun 2. Review.

PMID:
28579118
12.

MicroRNA-based molecular classification of papillary thyroid carcinoma.

Rosignolo F, Memeo L, Monzani F, Colarossi C, Pecce V, Verrienti A, Durante C, Grani G, Lamartina L, Forte S, Martinetti D, Giuffrida D, Russo D, Basolo F, Filetti S, Sponziello M.

Int J Oncol. 2017 May;50(5):1767-1777. doi: 10.3892/ijo.2017.3960. Epub 2017 Apr 7.

PMID:
28393181
13.

Silencing of hTERT blocks growth and migration of anaplastic thyroid cancer cells.

Maggisano V, Celano M, Lombardo GE, Lepore SM, Sponziello M, Rosignolo F, Verrienti A, Baldan F, Puxeddu E, Durante C, Filetti S, Damante G, Russo D, Bulotta S.

Mol Cell Endocrinol. 2017 Jun 15;448:34-40. doi: 10.1016/j.mce.2017.03.007. Epub 2017 Mar 10.

PMID:
28288903
14.

Expression of YAP1 in aggressive thyroid cancer.

Celano M, Mignogna C, Rosignolo F, Sponziello M, Iannone M, Lepore SM, Lombardo GE, Maggisano V, Verrienti A, Bulotta S, Durante C, Di Loreto C, Damante G, Russo D.

Endocrine. 2018 Jan;59(1):209-212. doi: 10.1007/s12020-017-1240-6. Epub 2017 Jan 24. No abstract available.

PMID:
28120182
15.

RET mutation and increased angiogenesis in medullary thyroid carcinomas.

Verrienti A, Tallini G, Colato C, Boichard A, Checquolo S, Pecce V, Sponziello M, Rosignolo F, de Biase D, Rhoden K, Casadei GP, Russo D, Visani M, Acquaviva G, Ferdeghini M, Filetti S, Durante C.

Endocr Relat Cancer. 2016 Aug;23(8):665-76. doi: 10.1530/ERC-16-0132. Epub 2016 Jul 8.

PMID:
27402614
16.

Expression of PAX8 Target Genes in Papillary Thyroid Carcinoma.

Rosignolo F, Sponziello M, Durante C, Puppin C, Mio C, Baldan F, Di Loreto C, Russo D, Filetti S, Damante G.

PLoS One. 2016 Jun 1;11(6):e0156658. doi: 10.1371/journal.pone.0156658. eCollection 2016.

17.

Risk Stratification of Neck Lesions Detected Sonographically During the Follow-Up of Differentiated Thyroid Cancer.

Lamartina L, Grani G, Biffoni M, Giacomelli L, Costante G, Lupo S, Maranghi M, Plasmati K, Sponziello M, Trulli F, Verrienti A, Filetti S, Durante C.

J Clin Endocrinol Metab. 2016 Aug;101(8):3036-44. doi: 10.1210/jc.2016-1440. Epub 2016 May 17.

PMID:
27186860
18.

Fibronectin-1 expression is increased in aggressive thyroid cancer and favors the migration and invasion of cancer cells.

Sponziello M, Rosignolo F, Celano M, Maggisano V, Pecce V, De Rose RF, Lombardo GE, Durante C, Filetti S, Damante G, Russo D, Bulotta S.

Mol Cell Endocrinol. 2016 Aug 15;431:123-32. doi: 10.1016/j.mce.2016.05.007. Epub 2016 May 10.

PMID:
27173027
19.

HABP2 Mutation and Nonmedullary Thyroid Cancer.

Sponziello M, Durante C, Filetti S.

N Engl J Med. 2015 Nov 19;373(21):2085-6. doi: 10.1056/NEJMc1511631. No abstract available.

PMID:
26581004
20.

Molecular profiles of cancer stem-like cell populations in aggressive thyroid cancers.

Dima M, Pecce V, Biffoni M, Di Gioia CR, Tallini G, Biffoni M, Rosignolo F, Verrienti A, Sponziello M, Damante G, Russo D, Durante C.

Endocrine. 2016 Jul;53(1):145-56. doi: 10.1007/s12020-015-0739-y. Epub 2015 Sep 14.

PMID:
26370117
21.

A NOVEL DOUBLE MUTATION VAL648ILE AND VAL804LEU OF RET PROTO-ONCOGENE IN MULTIPLE ENDOCRINE NEOPLASIA TYPE 2.

Verrienti A, Carbone A, Bellitti P, Fabiano MC, De Rose RF, Maranghi M, Lucia P, Durante C, Rosignolo F, Pecce V, Sponziello M, Puppin C, Costante G, Bruno R.

Endocr Pract. 2015 Nov;21(11):1248-54. doi: 10.4158/EP15838.OR. Epub 2015 Aug 6.

PMID:
26247112
22.

Reduced expression of THRβ in papillary thyroid carcinomas: relationship with BRAF mutation, aggressiveness and miR expression.

Rosignolo F, Maggisano V, Sponziello M, Celano M, Di Gioia CR, D'Agostino M, Giacomelli L, Verrienti A, Dima M, Pecce V, Durante C.

J Endocrinol Invest. 2015 Dec;38(12):1283-9. doi: 10.1007/s40618-015-0309-4. Epub 2015 May 24.

PMID:
26003825
23.

Somatic amplifications and deletions in genome of papillary thyroid carcinomas.

Passon N, Bregant E, Sponziello M, Dima M, Rosignolo F, Durante C, Celano M, Russo D, Filetti S, Damante G.

Endocrine. 2015 Nov;50(2):453-64. doi: 10.1007/s12020-015-0592-z. Epub 2015 Apr 12.

PMID:
25863487
24.

PDE5 expression in human thyroid tumors and effects of PDE5 inhibitors on growth and migration of cancer cells.

Sponziello M, Verrienti A, Rosignolo F, De Rose RF, Pecce V, Maggisano V, Durante C, Bulotta S, Damante G, Giacomelli L, Di Gioia CR, Filetti S, Russo D, Celano M.

Endocrine. 2015 Nov;50(2):434-41. doi: 10.1007/s12020-015-0586-x. Epub 2015 Apr 3.

PMID:
25837309
25.

Clinical exome performance for reporting secondary genetic findings.

Park JY, Clark P, Londin E, Sponziello M, Kricka LJ, Fortina P.

Clin Chem. 2015 Jan;61(1):213-20. doi: 10.1373/clinchem.2014.231456. Epub 2014 Nov 20.

26.

Epigenetic-related gene expression profile in medullary thyroid cancer revealed the overexpression of the histone methyltransferases EZH2 and SMYD3 in aggressive tumours.

Sponziello M, Durante C, Boichard A, Dima M, Puppin C, Verrienti A, Tamburrano G, Di Rocco G, Redler A, Lacroix L, Bidart JM, Schlumberger M, Damante G, Russo D, Filetti S.

Mol Cell Endocrinol. 2014 Jul 5;392(1-2):8-13. doi: 10.1016/j.mce.2014.04.016. Epub 2014 May 9.

PMID:
24813658
27.

Overexpression of genes involved in miRNA biogenesis in medullary thyroid carcinomas with RET mutation.

Puppin C, Durante C, Sponziello M, Verrienti A, Pecce V, Lavarone E, Baldan F, Campese AF, Boichard A, Lacroix L, Russo D, Filetti S, Damante G.

Endocrine. 2014 Nov;47(2):528-36. doi: 10.1007/s12020-014-0204-3. Epub 2014 Feb 26.

PMID:
24569963
28.

Indoleamine 2,3-dioxygenase 1 (IDO1) is up-regulated in thyroid carcinoma and drives the development of an immunosuppressant tumor microenvironment.

Moretti S, Menicali E, Voce P, Morelli S, Cantarelli S, Sponziello M, Colella R, Fallarino F, Orabona C, Alunno A, de Biase D, Bini V, Mameli MG, Filetti S, Gerli R, Macchiarulo A, Melillo RM, Tallini G, Santoro M, Puccetti P, Avenia N, Puxeddu E.

J Clin Endocrinol Metab. 2014 May;99(5):E832-40. doi: 10.1210/jc.2013-3351. Epub 2014 Feb 11.

PMID:
24517146
29.

Performance of exome sequencing for pharmacogenomics.

Londin ER, Clark P, Sponziello M, Kricka LJ, Fortina P, Park JY.

Per Med. 2014;12(2):109-115.

30.

Different expression of TSH receptor and NIS genes in thyroid cancer: role of epigenetics.

D'Agostino M, Sponziello M, Puppin C, Celano M, Maggisano V, Baldan F, Biffoni M, Bulotta S, Durante C, Filetti S, Damante G, Russo D.

J Mol Endocrinol. 2014 Jan 30;52(2):121-31. doi: 10.1530/JME-13-0160. Print 2014 Apr.

PMID:
24353283
31.

Molecular differences between human thyroid follicular adenoma and carcinoma revealed by analysis of a murine model of thyroid cancer.

Sponziello M, Lavarone E, Pegolo E, Di Loreto C, Puppin C, Russo MA, Bruno R, Filetti S, Durante C, Russo D, Di Cristofano A, Damante G.

Endocrinology. 2013 Sep;154(9):3043-53. doi: 10.1210/en.2013-1028. Epub 2013 Jun 10.

32.

Cooperation of histone deacetylase inhibitors SAHA and valproic acid in promoting sodium/iodide symporter expression and function in rat Leydig testicular carcinoma cells.

Maggisano V, Puppin C, Celano M, D'Agostino M, Sponziello M, Micali S, Navarra M, Damante G, Filetti S, Russo D.

Endocrine. 2014 Feb;45(1):148-52. doi: 10.1007/s12020-013-9972-4. Epub 2013 May 1.

PMID:
23636804
33.

Sodium/iodide symporter is expressed in the majority of seminomas and embryonal testicular carcinomas.

Micali S, Maggisano V, Cesinaro A, Celano M, Territo A, Reggiani Bonetti L, Sponziello M, Migaldi M, Navarra M, Bianchi G, Filetti S, Russo D.

J Endocrinol. 2013 Jan 18;216(2):125-33. doi: 10.1530/JOE-12-0495. Print 2013 Feb. Review.

PMID:
23117572
34.

Increased expression of pro-angiogenic factors and vascularization in thyroid hyperfunctioning adenomas with and without TSH receptor activating mutations.

Celano M, Sponziello M, Tallini G, Maggisano V, Bruno R, Dima M, Di Oto E, Redler A, Durante C, Sacco R, Filetti S, Russo D.

Endocrine. 2013 Feb;43(1):147-53. doi: 10.1007/s12020-012-9747-3. Epub 2012 Jul 20.

PMID:
22815044
35.

Sunitinib exerts only limited effects on the proliferation and differentiation of anaplastic thyroid cancer cells.

D'Agostino M, Voce P, Celano M, Sponziello M, Moretti S, Maggisano V, Verrienti A, Durante C, Filetti S, Puxeddu E, Russo D.

Thyroid. 2012 Feb;22(2):138-44. doi: 10.1089/thy.2011.0060. Epub 2011 Dec 22.

PMID:
22191389
36.

TSH receptor extracellular region mutations in thyroid functioning nodules: further evidence for the functional role of this region in the receptor activation.

Russo D, Costante G, Bruno R, Sponziello M, Tamburrano G, Dima M, Sacco R, Giacomelli L, Durante C, Filetti S.

Endocrine. 2011 Dec;40(3):492-4. doi: 10.1007/s12020-011-9525-7. Epub 2011 Aug 24. No abstract available.

PMID:
21863340
37.

Sunitinib inhibits tumor vascularity and growth but does not affect Akt and ERK phosphorylation in xenograft tumors.

Voce P, D'Agostino M, Moretti S, Sponziello M, Rhoden K, Calcinaro F, Tamburrano G, Tallini G, Puxeddu E, Filetti S, Russo D, Durante C.

Oncol Rep. 2011 Nov;26(5):1075-80. doi: 10.3892/or.2011.1422. Epub 2011 Aug 17.

PMID:
21850379
38.

BRAF(V600E) mutation and expression of proangiogenic molecular markers in papillary thyroid carcinomas.

Durante C, Tallini G, Puxeddu E, Sponziello M, Moretti S, Ligorio C, Cavaliere A, Rhoden KJ, Verrienti A, Maranghi M, Giacomelli L, Russo D, Filetti S.

Eur J Endocrinol. 2011 Sep;165(3):455-63. doi: 10.1530/EJE-11-0283. Epub 2011 Jun 8.

PMID:
21653734
39.

Growth factor receptors gene expression and Akt phosphorylation in benign human thyroid nodules are unaffected by chronic thyrotropin suppression.

Sponziello ML, Bruno R, Durante C, D'Agostino M, Corradino R, Giannasio P, Ciociola E, Ferretti E, Maranghi M, Verrienti A, De Toma G, Filetti S, Russo D.

Horm Metab Res. 2011 Jan;43(1):22-5. doi: 10.1055/s-0030-1265226. Epub 2010 Sep 30.

PMID:
20886414
40.

The transdehydrogenase genes KlNDE1 and KlNDI1 regulate the expression of KlGUT2 in the yeast Kluyveromyces lactis.

Saliola M, D'Amici S, Sponziello M, Mancini P, Tassone P, Falcone C.

FEMS Yeast Res. 2010 Aug 1;10(5):518-26. doi: 10.1111/j.1567-1364.2010.00631.x. Epub 2010 Apr 8.

41.

A novel de novo germ-line V292M mutation in the extracellular region of RET in a patient with phaeochromocytoma and medullary thyroid carcinoma: functional characterization.

Castellone MD, Verrienti A, Magendra Rao D, Sponziello M, Fabbro D, Muthu M, Durante C, Maranghi M, Damante G, Pizzolitto S, Costante G, Russo D, Santoro M, Filetti S.

Clin Endocrinol (Oxf). 2010 Oct;73(4):529-34. doi: 10.1111/j.1365-2265.2009.03757.x.

PMID:
20039896
42.

Regulation of sodium/iodide symporter and lactoperoxidase expression in four human breast cancer cell lines.

Sponziello M, Scipioni A, Durante C, Verrienti A, Maranghi M, Giacomelli L, Ferretti E, Celano M, Filetti S, Russo D.

J Endocrinol Invest. 2010 Jan;33(1):2-6. doi: 10.3275/6522. Epub 2009 Sep 30.

PMID:
19794300
43.

Characterization of KlGUT2, a gene of the glycerol-3-phosphate shuttle, in Kluyveromyces lactis.

Saliola M, Sponziello M, D'Amici S, Lodi T, Falcone C.

FEMS Yeast Res. 2008 Aug;8(5):697-705. doi: 10.1111/j.1567-1364.2008.00386.x. Epub 2008 May 22.

Supplemental Content

Loading ...
Support Center